

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-0409US1	Application No. 10/561,014
	Applicant Shuchong Pan et al.		
	Filing Date June 6, 2006	Group Art Unit 1649	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	4,496,544	01/29/85	Needleman			
	2	5,212,286	05/18/93	Lewicki et al.			
	3	5,846,932	12/08/98	Lowe et al.			
	4	6,376,207	04/23/02	Mischal et al.			
	5	6,818,619	11/16/04	Burnett, Jr. et al.			
	6	6,849,714	02/01/05	Bridon et al.			
	7	6,887,470	05/03/05	Bridon et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	8	WO 95/24419	09/14/95	WO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	9	GenBank Accession No. BQ130005 dated 7/15/03
	10	GenBank Accession No. BQ130258 dated 7/15/03
	11	GenBank Accession No. M25296 dated 4/27/93
	12	Ogawa et al., "Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene," <u>J. Clin. Invest.</u> , 1994, 93(5):1911-1921
	13	Valli et al., "Review of 10 years of the clinical use of brain natriuretic peptide in cardiology," <u>J. Lab. Clin. Med.</u> , 1999, 134(5):437-444

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.Y.W./

Examiner Signature /Chang-Yu Wang/	Date Considered 04/09/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	